About the American Lung Association COVID-19 and Emerging Respiratory Viruses Research Award

There is an urgent need to better understand the pathobiology and both long term and immediate clinical implications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection that leads to the morbidity and mortality seen with COVID-19, as well as increase knowledge about the potential emerging threat of other novel respiratory viruses. We are looking for proposals to advance research against emerging respiratory pathogens like SARS-CoV-2. All research must directly be related to COVID-19 or other viral respiratory threats that may arise in the future.

The Lung Association is interested in applications that address the following types of clinical, basic, translational, and population health questions:

- A new understanding of the basic biology of respiratory viruses that could lead to better treatment and prevention
- Understanding host factors that alter response to these infections
- Understanding individual, regional, or social factors increasing or decreasing community spread of COVID-19 and other respiratory viruses
- Case tracking and epidemiological approaches to understanding COVID-19 and other respiratory viruses

About the Funding Opportunity

The American Lung Association COVID-19 and Emerging Respiratory Viruses Research Award is for $100,000 per year for two years. The award is intended to support independent investigators with a stellar track record of accomplishment, who have the potential to advance our knowledge and understanding of COVID-19 and other novel respiratory viruses with epidemic potential.

Successful applicants will be independent investigators with strong evidence of ongoing excellence and productivity in a related field.

Grants are subject to annual review and may be granted for up to two years. The second year of support is contingent on demonstration of satisfactory progress, as well as the availability of funding from the Lung Association.

No more than 25% of the requested budget may be used for an awardee’s salary and/or fringe benefits and no more than 30% of the total award budget may be used to fund the purchase of permanent equipment. Grant funds may be used for the salary and fringe benefit costs of personnel other than the Applicant.

Key Dates:
February 18, 2021: LOIs are due
March 1, 2021: LOI Results. ProposalCENTRAL opens to invited applicants
April 30, 2021: Application deadline is April 30, 2021, 11:59 PM ET
June 30, 2021: Outcome notifications are sent to all applicants
Important Notes
Applicants are limited to submitting only one COVID-19 application per cycle to the Lung Association.

It is recommended that applicants submit projects to the appropriate Institutional Animal Care and Use of Committee (IACUC) and human subjects Institutional Review Board (IRB) at the time of application or before. Copies of the approvals must be provided to the American Lung Association prior to funding.

Eligibility Requirements
This funding opportunity does not limit the applicants based on academic rank or discipline. It requires only evidence of faculty status at a nonprofit academic institution, and independence beyond the fellowship/training stage. The institution must commit that the applicant is eligible to be continuously employed throughout the duration of the grant term and should state so in the Department Chair's Letter of Support.

Experience and Productivity
At the time of application, the applicant must hold a doctoral degree and have a faculty appointment or equivalent with demonstrated institutional commitment (salary support, research space as evidenced by a Department Chair or equivalent letter) in a recognized academic not-for-profit research institution.

Letter of Intent (LOI)

A letter of intent is required for the COVID-19 and Emerging Respiratory Viruses Research Award. Interested applicants must submit an LOI to the American Lung Association through proposalCENTRAL by February 18, 2021.

Outcome notifications of the first stage of the application process will be emailed to applicants in early March. Full proposals will be due April 30, 2021.

Requirements for the Letter of Intent Submission:

- A 1-page Letter of Intent including brief descriptions on the:
  - Rationale and Significance of the research project
  - Specific Aims and Hypotheses (may be modified slightly in full application)
  - Overall experimental approach

- Applicant Biosketch

Peer Review
Applications determined by administrative review to be eligible for funding will go through a rigorous external peer review process. Factors considered when reviewing applications include:

- Scientific merit, technical feasibility, innovation and project relevance to the mission of the American Lung Association
- Applicant’s education, experience, and contributions to the field
- Research environment
• Likelihood that the project will advance our current understanding of the science and impact patients
• Department Chair (or equivalent) letter confirming faculty status and institutional commitment

Once funding decisions have been made all applicants will be notified via email. We cannot respond to telephone or email requests for results.

Invited applicants will have until April 30, 2021 to submit their full proposal.